Oxurion Provides Update on Clinical Pipeline Progress

NEXT STORY
Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
PREV STORY
Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061

-ZGN-1061 in Phase I Development for Severe and Complicated Obesity Indications- - Suspending Development ...

author_avatar
NASDAQ Market News

Myriad Genetics to Highlight New Clinical Outcomes Data on myPath(R) Melanoma at the American Society of Dermatopathology Annual Meeting

SALT LAKE CITY, Oct. 8, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a ...

author_avatar
NASDAQ Market News

Cesca Therapeutics Inc. Announces Pricing of Public Offering of up to 900,000 shares of Common Stock

RANCHO CORDOVA, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) ...

author_avatar
NASDAQ Market News